NVO - Novo Nordisk details heart benefits of weight loss drug from Phase 3 trial
2023-11-11 10:25:00 ET
More on Novo Nordisk
- Novo Nordisk: Price Could Still Be Justified
- Novo Nordisk A/S (NVO) Q3 2023 Earnings Call Transcript
- Novo Nordisk Milks The Obesity Cash Cow - How Long Will It Last?
- Novo Nordisk pledges $6B to expand API production
- Eli Lilly wins FDA approval for weight loss therapy (update)
For further details see:
Novo Nordisk details heart benefits of weight loss drug from Phase 3 trial